Nanomedicine enables spatiotemporally regulating macrophage-based cancer immunotherapy

• Published in: Biomaterials Vol. 268; p. 120552
• Main Authors: Zhao, Yong-Dan, Muhetaerjiang, Mamuti, An, Hong-Wei, Fang, Xiaohong, Zhao, Yuliang, Wang, Hao
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.01.2021
• Subjects: Cancer immunotherapy; Nanomedicine; Spatiotemporal control; Tumor associated macrophages; CXCL; Tumor associated macrophages; M1; M-CSF; M2; EPR; MHC; GCT-TS; Cancer immunotherapy; TNF; MPS; NF-κB; IFN-γ; Arg-1; Th; PI3K; GM-CSF; IDO; VEGFR; iNOS; IL; TRAIL; dt-GCT; SIRPα; CSF-1; NKT; ROS; BTK; CXCR; PD-1; NK; CSF1R; FDA; TCR; miRNAs; IFP; TAMs; Spatiotemporal control; PD-L1; TGF-β; CTLA-4; Nanomedicine; HIF1α; PGE2; CD; VCAM1; NSCLC; EGF; Tregs; VEGF; MMPs; AKT; TME; CCL; ECM; NPs; MDSCs; STAT; CCR; PEG; PLGA; APC; PDGF; TLRs
• ISSN: 0142-9612; 1878-5905
• DOI: 10.1016/j.biomaterials.2020.120552

Cancer immunotherapy, leveraging the host's coordinated immune system to fight against tumor has been clinically validated. However, the modest response owing to the multiple ways of tumor immune evasion is one of the challenges in cancer immunotherapy. Tumor associated macrophages (TAMs), as a major component of the leukocytes infiltrating in all tumors, play crucial roles in driving cancer initiation, progress and metastasis via multiple mechanisms such as mediating chronic inflammation, promoting angiogenesis, taming protective immune responses, and supporting migration and intravasation. TAMs targeted therapeutics have achieved remarkable successes in clinical trials mostly through the use of small-molecule agents and antibodies. However, efforts for further application have met with challenges of limited efficacy and safety. Nanomaterials can provide versatile approaches to realize the superior spatiotemporal control over immunomodulation to amplify immune responses, ultimately enhancing the therapeutic benefits and reducing toxicity. Here, the potential drugs used in TAM-centered cancer treatment in clinic are summarized and the recent advances of TAMs targeted nanomedicines in this filed are highlighted. More importantly, we focus on how nanomedicine can exert their advantages in spatial and temporal control of immunomodulation. [Display omitted]